Treated Hepatitis B Infection May Be a Positive Prognostic Factor in ... - AJMC.com Managed Markets Network

Patients with hepatitis B virus (HBV)–associated diffuse large B-cell lymphoma (DLBCL) who received antiviral treatment exhibited superior outcomes following treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) compared with patients with HBV-unassociated DLBCL, recent study results suggest.

Specifically, following treatment with R-CHOP, these individuals had a significantly longer time to progression (TTP) and overall survival (OS).

Findings were published in the journal Clinical and Molecular Hepatology.

Infection with HBV is a known risk factor for non-Hodgkin lymphoma, while previous research has shown chronic hepatitis B (CHB) is a key risk factor for DLBCL, authors wrote.

To better understand whether antiviral treatment mitigates disease progression or HBV-associated NHL or DLBCL recurrence, investigators carried out a retrospective study of patients presenting to 2 hospitals in South Korea.

All participants were diagnosed with DLBCL and underwent R-CHOP as first-line chemotherapy between 2012 and 2019. Any individual who was diagnosed with other malignancies 5 years before DLBCL diagnosis, had concurrent viral infections, or had completed an organ transplant was excluded from the study.

A total of 928 patients were included in the analysis and all individuals with CHB received antiviral treatment, authors explained. Of the patients included, 82 had an HBV infection and 846 did not.

CT or PET-CT were carried out to determine treatment response following six cycles of R-CHOP. After the last round of chemotherapy, a follow-up CT or PET-CT was carried out every three months for one year.

Patients had a median follow-up time of 50.5 months.

Analyses revealed:

  • There was a longer TTP in the CHB group than the non-CHB group both before inverse probability of treatment weighting (IPTW; adjusted HR, 0.49; 95% CI, 0.29-0.82; P = .007) and after IPTW (adjusted HR, 0.42; 95% CI, 0.26-0.70; P < .001).
  • The CHB group had a longer OS than the non-CHB group both before IPTW (HR, 0.55; 95% CI, 0.33-0.92; log-rank P = .02) and after IPTW (HR, 0.53; 95% CI, 0.32-0.99; log-rank P = .02).
  • Liver-related deaths did not occur in the non-CHB group.
  • Two deaths occurred in the CHB group due to hepatocellular carcinoma and acute liver failure, respectively.

Overall, patients with CHB exhibited a 51% to 58% lower risk of progression and had a longer OS and progression-free survival than those without CHB.

Before antivirals were developed, many patients with lymphoma "died of severe hepatitis caused by HBV reactivation," researchers explained.

However, thanks to antiviral prophylaxis, current guidelines suggest this treatment route for patients receiving chemotherapeutic agents like rituximab.

"Our study shows that current HBV infection is a favorable prognostic factor for DLBCL patients in the era of antiviral prophylaxis," authors wrote.

The positive outcomes seen in the current study could be due to the fact that lowering a patient's HBV viral load curbs HBV-driven antigen stimulation of B-cells. This can inhibit the lymphoma's progression or recurrence, researchers said.

Patients with a high HBV viral load also have dysfunctional innate and adaptive immune systems, contributing to decreased immune surveillance, but because antiviral treatment restores this surveillance, it lowers the risk of recurrent lymphoma, they added.

The retrospective nature of the study means selection bias may have been present, marking a limitation. In addition, because the analysis only included patients who underwent R-CHOP, those who completed different chemotherapies may exhibit different clinical outcomes than those reported.

"In conclusion, HBV infection was a favorable prognostic factor associated with a prolonged TTP, progression-free survival, and OS in HBV-related DLBCL patients who received antiviral medication prior to R-CHOP chemotherapy," authors wrote.

Reference

Park J, Chung SW, Lee YB, et al. Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma. Clin Mol Hepatol. Published online May 17, 2023. doi:10.3350/cmh.2023.0057

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

His Apple Watch warned of an irregular heart rate. Turns out he was having a heart attack | Globalnews.ca - Global News Toronto

Image
A Nova Scotia man is thanking a digital watch for saving his life. Travis Chalmers, of Elmsdale, N.S., said he was outside playing road hockey with his son when he suddenly experienced a "warm sensation" in his chest area and a splitting headache. "I just thought it was a flu or cold coming on and my seasonal allergies had been kicking in. I thought it was flu-like symptoms and shrugged it off," he said. But to Chalmers' surprise, an otherwise laidback afternoon eventually took a scary turn when he glanced at his wrist. A notification from his Apple Watch led him to discover he was experiencing a heart attack. "About a half hour later, I'm laying down with my daughter and my heart rate is still beating out of my chest," he continued, adding that he monitored his heart rate on his Apple Watch for the next few hours. The watch indicated that he was experiencing atrial fibrillation, a rapid heart rhythm that can increase the ris...
Read more

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w...
Read more

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

Image
“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times Posted: 12 Dec 2019 11:25 AM PST It was chest pain that brought the 34-year-old woman to the emergency room at Montefiore Medical Center in the Bronx. She'd been coughing for days, but that morning the pain was so bad she was worried that it had turned into pneumonia. She tried to tough it out, but when it was no better by the end of the day, she decided to go to the E.R. It took a few hours, but finally the physician assistant caring for her in the E.R. brought some good news. She didn't have pneumonia; she didn't have a clot in her lungs. This was just muscle strain from coughing. The year before, she was told she had asthma. She was given inhalers to stop the coughing and wheezing, but they didn't seem to do much. So she didn'...
Read more